ChemoCentryx Inc expected to post a loss of 40  cents a share - Earnings Preview

Churchill Capital XI

27/04/2021 21:35

* ChemoCentryx Inc  CCXI.OQ   CCXI.O  is expected to show a rise
in quarterly revenue when it reports results on April 29.
* The San Carlos, California-based company is expected to report
 a 32.0% increase in revenue to $7.929 million from $6.01
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data.​​
​* Refinitiv's mean analyst estimate for ChemoCentryx Inc is for
a loss of 40 cents per share. For the same quarter last year,
the company reported a loss of 35 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had risen by about 2.5%
in the last three months.​
* Wall Street's median 12-month price target for ChemoCentryx
Inc is $84​, about 43.6% above​ its last closing price
of $47.36. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.34       -0.33      -0.43     Missed  -29.2
 Sep. 30 2020  -0.31       -0.31      -0.35     Missed  -12.4
 Jun. 30 2020  -0.34       -0.34      0.29      Beat    185.3​
 Mar. 31 2020  -0.30       -0.30      -0.35     Missed  -16.7
 Dec.          -0.25​      -0.26      -0.26     Met     0.6​
 31​ 2019​                                              
 Sep. 30 2019  -0.28       -0.28      -0.22     Beat    21.4​
 Jun. 30 2019  -0.20       -0.22      -0.26     Missed  -20.5
 Mar. 31 2019  -0.24       -0.24      -0.23     Beat    3
 This summary was machine generated April 27 at 20:35 GMT.  All
figures in US dollars unless otherwise stated